Disease Domain | Count |
---|---|
Neoplasms | 2 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 2 |
AAV based gene therapy | 1 |
Biological products | 1 |
Target- |
Mechanism Gene transference |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism CFTR gene modulators |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism Nicotinic receptors agonists |
Active Org.- |
Originator Org. |
Active Indication- |
Inactive Indication |
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Sep 2024 |
Sponsor / Collaborator |
Start Date01 May 2024 |
Sponsor / Collaborator |
Start Date01 May 2024 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Aquaporin-1 CRISPR/Cas9 gene therapy (University of Bristol/UCL Institute of Ophthalmology/University of Cambridge) | Glaucoma More | Preclinical |
CPD3.1 ( TEAD1 x YAP1 ) | Neoplasms More | Preclinical |
AR-C155858 ( MCT1 x MCT2 ) | Breast Cancer More | Preclinical |
RCT-223 ( CFTR ) | Cystic Fibrosis More | Preclinical |
[3H]BU-97001 ( δ opioid receptor ) | Central Nervous System Diseases More | Pending |